Results 41 to 50 of about 2,650 (185)
Bioengineering of Antibody Fragments: Challenges and Opportunities. [PDF]
, 2023 Antibody fragments are used in the clinic as important therapeutic proteins for treatment of indications where better tissue penetration and less immunogenic molecules are needed.
Dolphin, Colin +13 more
core +4 more sources
Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
Case Reports in Ophthalmology, 2022 The efficacy of intravitreal anti-VEGF may be reduced in vitrectomized eyes due to accelerated drug clearance. Given its longer durability, brolucizumab may represent a suitable therapeutic option.
Emilia Maggio +3 more
doaj +1 more source
Scientific Reports, 2022 We evaluated 1-year outcomes of loading phase treatment followed by maintenance treatment using a treat-and-extend (TAE) regimen with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) associated with type 1 macular ...
Hidetaka Matsumoto +4 more
doaj +1 more source
Ophthalmology and Therapy, 2023 Introduction The HAWK and HARRIER studies evaluated the efficacy and safety of brolucizumab versus aflibercept in treatment-naïve eyes with neovascular age-related macular degeneration.
Ramin Tadayoni +11 more
doaj +1 more source
High-Yield Biosynthesis Process and Characterization of Brolucizumab
Pharmaceutical FrontsBrolucizumab was the first single-chain fragment variable (scFv) antibody approved by the FDA for the treatment of age-related macular degeneration (AMD). However, the manufacturing process of brolucizumab remains rarely reported.
Xiaoyue Hu +5 more
doaj +1 more source
Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis
Clinical Ophthalmology, 2023 Nicholas J Saba,1 Scott D Walter2 1Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn, NY, USA; 2Retina Consultants, PC, Hartford, CT, USACorrespondence: Scott D Walter, Retina Consultants, PC, 43 Woodland Street, Hartford, CT, USA ...
Saba NJ, Walter SD
doaj
American Journal of Ophthalmology Case Reports, 2022 Purpose: To report on a case of successful treatment of intraocular inflammation (IOI) secondary to brolucizumab intravitreal injection that responded to a single sub-Tenon injection of triamcinolone.
Shree K. Kurup +3 more
doaj +1 more source
Novel and investigational therapies for wet and dry age-related macular degeneration [PDF]
, 2022 Funding Information: The authors are thankful to the Institute of Chemical Technology, Mumbai, India for providing facilities to carry out this work. V.J.is supported by a personal research grant from the Finnish Cultural Foundation (Ingrid, Toini and ...
Dyawanapelly, Sathish +4 more
core +1 more source
Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab. [PDF]
Background: Treatment cessation due to a dry retina has not been systematically addressed in diabetic macular edema (DME). In three out of four patients receiving 6 mg of brolucizumab in the KITE study, treatment was terminated after the study ended ...
Garweg, Justus G, Steinhauer, Sonja
core +1 more source